Last reviewed · How we verify
Intraarticular steroid
Intraarticular steroid is a Small molecule drug developed by Frederiksberg University Hospital. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Intraarticular steroid |
|---|---|
| Sponsor | Frederiksberg University Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Upper respiratory tract infection
- Muscle spasms
- Back pain
- Joint swelling
- Joint crepitation
- Joint effusion
- Influenza
- Nasopharyngitis
- Ligament sprain
- Oedema Peripheral
- Upper Respiratory Tract Infection
Key clinical trials
- Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)
- Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Corticosteroid Meniscectomy Randomized Trial (PHASE4)
- Efficacy of IPACK Block Combined With Intra-articular Steroid Injection in Advanced Knee Osteoarthritis: A Retrospective Cohort Study
- Knee Injections for Obese Patients With Knee Arthritis (PHASE4)
- A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder (PHASE4)
- Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraarticular steroid CI brief — competitive landscape report
- Intraarticular steroid updates RSS · CI watch RSS
- Frederiksberg University Hospital portfolio CI
Frequently asked questions about Intraarticular steroid
What is Intraarticular steroid?
Who makes Intraarticular steroid?
What development phase is Intraarticular steroid in?
What are the side effects of Intraarticular steroid?
Related
- Manufacturer: Frederiksberg University Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing